AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36155119 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (500 mg/day for 90 days)
Number of subjects: 35
Study 36155119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 33285347 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based therapy
Number of subjects: 48
Study 33285347 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower delusional distress at discharge
Number of subjects: 48
Study 33285347 — intervention group
Group type: EXPERIMENTAL
Intervention: Black and Minority Ethnic (BME) background
Number of subjects: 48
Study 33285347 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharged to an Early Intervention (EI) service
Number of subjects: 48
Study 33027506 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic Threat condition
Number of subjects: 103
Study 33027506 — intervention group
Group type: COMPARATOR
Intervention: No-Threat Control condition
Number of subjects: 103
Study 35331015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fab antivenom
Number of subjects: 0
Study 35331015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32331016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (20-80 mg/d)
Number of subjects: 306
Study 32331016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to lurasidone)
Number of subjects: 306
Study 34539185 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.5 mg loading dose, followed by 0.5 mg b.i.d. for one week and 0.5 mg per day for 28 days)
Number of subjects: 103
Study 34539185 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 103
Study 34539185 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 103
Study 34539185 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine and Standard treatment
Number of subjects: 103
Study 32678713 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: PBM with power 250 mW, energy density 8.8 J/cm2 for WHO grade 3 and 15.5 J/cm2 for WHO grade 4.
Number of subjects: 0
Study 32678713 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: PBM with power 500 mW, energy density as in group A.
Number of subjects: 0
Study 32678713 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: PBM with power 250 mW, energy density was half of groups A and B.
Number of subjects: 0
Study 34296544 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX-T (gemcitabine 1000 mg/m² and oxaliplatin 50 mg/m² on day 1 and day 8 plus erlotinib 100 mg daily for 3 weeks)
Number of subjects: 65
Study 34296544 — intervention group
Group type: COMPARATOR
Intervention: GT (gemcitabine 1000 mg/m² on day 1 and day 8 plus erlotinib 100 mg daily for 3 weeks)
Number of subjects: 65
Study 34296544 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX-T
Number of subjects: 65
Study 34296544 — intervention group
Group type: COMPARATOR
Intervention: GT
Number of subjects: 65
Study 33009572 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 33 phage vector with optimized copy number of peptides displayed on the phage surface.
Number of subjects: 0
Study 35881893 — intervention group
Group type: COMPARATOR
Intervention: Oral sildenafil (0.5‐2 mg/kg/6 hours)
Number of subjects: 40
Study 35881893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous milrinone (0.25‐0.75 mic/kg/min)
Number of subjects: 40
Study 34887636 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram integrating radiomics score and clinical factors
Number of subjects: 118
Study 34887636 — intervention group
Group type: COMPARATOR
Intervention: Radiomics score or only clinical factors (comparison to the nomogram)
Number of subjects: 118
Study 34887636 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk stratification based on the nomogram
Number of subjects: 118
Study 33028102 — intervention group
Group type: EXPERIMENTAL
Intervention: Xyloglucan/gelose plus ORS
Number of subjects: 50
Study 33028102 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ORS
Number of subjects: 50
Study 32317829 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported respiratory symptoms and asthma medication use among adolescents
Number of subjects: 1200
Study 32317829 — intervention group
Group type: COMPARATOR
Intervention: Gender comparison in respiratory symptoms
Number of subjects: 1200
Study 32317829 — intervention group
Group type: COMPARATOR
Intervention: Frequency of wheezing attacks
Number of subjects: 1200
Study 34303265 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75/150 mg
Number of subjects: 2176
Study 34303265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2176
Study 34303265 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 2176
Study 32187913 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal feature subset prediction model using Fisher-NDA
Number of subjects: 144
Study 35510376 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (GMB)
Number of subjects: 2413
Study 34337072 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin titration goal of FBG≤6.1 mmol/L
Number of subjects: 71
Study 34337072 — intervention group
Group type: COMPARATOR
Intervention: Insulin titration goal of FBG≤5.6 mmol/L
Number of subjects: 71
Study 34337072 — intervention group
Group type: COMPARATOR
Intervention: Insulin titration goal of FBG≤7.0 mmol/L
Number of subjects: 71
Study 34907633 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of standard treatment for COVID-19 and hemoperfusion (hemofilter, HA330 D Javfron) for 4 hours, in 3 consecutive days
Number of subjects: 68
Study 34907633 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for COVID-19
Number of subjects: 68
Study 34907633 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of standard treatment for COVID-19 and hemoperfusion
Number of subjects: 68
Study 33232191 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive aerobic exercise (PAE), 24 weeks of supervised PAE, followed by self‐guided physical activity
Number of subjects: 43
Study 33232191 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive aerobic exercise (PAE) in cognitively impaired subgroup
Number of subjects: 43
Study 33232191 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive aerobic exercise (PAE) in total group and cognitively impaired subgroup
Number of subjects: 43
Study 33232191 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group, 24 weeks of habitual lifestyle, followed by supervised PAE
Number of subjects: 43
Study 35678134 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) with low Tacrolimus
Number of subjects: 100
Study 35678134 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate sodium with regular Tacrolimus (MPS)
Number of subjects: 100
Study 33589297 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent COVID-19 patients
Number of subjects: 33
Study 33589297 — intervention group
Group type: COMPARATOR
Intervention: Control group of 62 patients
Number of subjects: 33
Study 33138203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep health promotion program
Number of subjects: 218
Study 34315062 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary teaching intervention (game-based learning combined with clinical situation-based teaching) for 12 weeks
Number of subjects: 98
Study 34315062 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching
Number of subjects: 98
Study 35398532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin (FDX) 200 mg twice daily for 10 days
Number of subjects: 0
Study 35398532 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (VAN) 125 mg four times daily for 10 days followed by a 3-week vancomycin taper and pulse (VAN-T/P) regimen
Number of subjects: 0
Study 35398532 — intervention group
Group type: COMPARATOR
Intervention: Standard course of Vancomycin (VAN) 125 mg four times daily for 10 days
Number of subjects: 0
Study 33963496 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaussian models
Number of subjects: 0
Study 33963496 — intervention group
Group type: EXPERIMENTAL
Intervention: Data transformation and visual inspection
Number of subjects: 0
Study 33963496 — intervention group
Group type: COMPARATOR
Intervention: Non-Gaussian models and randomization techniques
Number of subjects: 0
Study 33963496 — intervention group
Group type: COMPARATOR
Intervention: Newly developed statistical methods
Number of subjects: 0
Study 33963496 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaussian mixed models
Number of subjects: 0
Study 33126374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical nursing pathway (CNP)
Number of subjects: 80
Study 33126374 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80
Study 33126374 — intervention group
Group type: EXPERIMENTAL
Intervention: CNP
Number of subjects: 80
Study 34698869 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 320
Study 34698869 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 320
Study 34698869 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 320
Study 32781433 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Setting (GS)
Number of subjects: 75
Study 32781433 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study 35260678 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 395
Study 35260678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 32985403 — intervention group
Group type: COMPARATOR
Intervention: Mandatory phone-call consult (PHONE)
Number of subjects: 791
Study 32985403 — intervention group
Group type: COMPARATOR
Intervention: Audiovisual consult (VIDEO)
Number of subjects: 791
Study 32985403 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (CONTROL)
Number of subjects: 791
Study 35691214 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulations applying only to unvaccinated adults (e.g., test fees, isolation pay, hospital prioritization)
Number of subjects: 0
Study 35691214 — intervention group
Group type: COMPARATOR
Intervention: Regulations applying to all adults
Number of subjects: 0
Study 33975993 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab-biosimilar (60 mg subcutaneous every 6 months for 1 year)
Number of subjects: 114
Study 33975993 — intervention group
Group type: COMPARATOR
Intervention: Denosumab-reference (60 mg subcutaneous every 6 months for 1 year)
Number of subjects: 114
Study 33975993 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab-biosimilar
Number of subjects: 114
Study 33975993 — intervention group
Group type: COMPARATOR
Intervention: Denosumab-reference
Number of subjects: 114
Study 33975993 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab-biosimilar and Denosumab-reference
Number of subjects: 114
Study 32533723 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 1 mg/kg
Number of subjects: 408
Study 32533723 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (DXM) 0.3 mg/kg
Number of subjects: 408
Study 34167868 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (35 mg) administered orally every week for 8 weeks
Number of subjects: 35
Study 34167868 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally every week for 8 weeks
Number of subjects: 35
Study 34167868 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (35 mg)
Number of subjects: 35
Study 34167868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 33482894 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin, 3 mg/kg/day for 15 days
Number of subjects: 60
Study 33482894 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 60
Study 33607462 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group with increased attention to threat and safety cues during extinction.
Number of subjects: 65
Study 33607462 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group during extinction recall.
Number of subjects: 65
Study 33607462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups attending to the safety cue during extinction.
Number of subjects: 65
Study 33607462 — intervention group
Group type: COMPARATOR
Intervention: Control group during extinction recall.
Number of subjects: 65
Study 32448392 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-h nutrient interruption
Number of subjects: 70
Study 32448392 — intervention group
Group type: COMPARATOR
Intervention: 12-h up-to-calculated-target feeding
Number of subjects: 70
Study 32369655 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Acetyl zingerone (AZ) applied twice daily for 8 weeks
Number of subjects: 31
Study 32369655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle base cream) applied twice daily for 8 weeks
Number of subjects: 31
Study 32466660 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pill (CDDP)
Number of subjects: 160
Study 35607923 — intervention group
Group type: EXPERIMENTAL
Intervention: Permobil Explorer Mini
Number of subjects: 24
Study 35607923 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ride-on toy car
Number of subjects: 24
Study 35607923 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Engagement in Daily Life
Number of subjects: 24
Study 33992437 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTAVAC
Number of subjects: 450
Study 33992437 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTAVAC 5D
Number of subjects: 450
Study 33992437 — intervention group
Group type: COMPARATOR
Intervention: ROTARIX
Number of subjects: 450
Study 32946503 — intervention group
Group type: EXPERIMENTAL
Intervention: epsilon-tau procedure
Number of subjects: 0
Study 35041591 — intervention group
Group type: EXPERIMENTAL
Intervention: Paresthesia mapping lead
Number of subjects: 43
Study 35041591 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomic placement lead
Number of subjects: 43
Study 35041591 — intervention group
Group type: COMPARATOR
Intervention: Both lead placement groups
Number of subjects: 43
Study 33721055 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) supplementation for 3 months
Number of subjects: 32
Study 33721055 — intervention group
Group type: COMPARATOR
Intervention: Control group (Se−)
Number of subjects: 32
Study 32305794 — intervention group
Group type: EXPERIMENTAL
Intervention: LUD group (received 15-30° left uterine displacement after SAB, n=30)
Number of subjects: 60
Study 32305794 — intervention group
Group type: EXPERIMENTAL
Intervention: LUD group
Number of subjects: 60
Study 32305794 — intervention group
Group type: COMPARATOR
Intervention: non-LUD group (no LUD after SAB, n=30)
Number of subjects: 60
Study 32305794 — intervention group
Group type: COMPARATOR
Intervention: non-LUD group
Number of subjects: 60
Study 35065657 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-arm-assisted TKR with VerasenseTM
Number of subjects: 90
Study 35065657 — intervention group
Group type: COMPARATOR
Intervention: Manual TKR (standard of care)
Number of subjects: 90
Study 33453410 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary proteomics analysis in CKD patients
Number of subjects: 36
Study 33453410 — intervention group
Group type: COMPARATOR
Intervention: Proteomics analysis of kidney tissue from a rat CKD model (5/6 nephrectomy)
Number of subjects: 36
Study 33453410 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation analyses for protein S and galectin-1
Number of subjects: 36
Study 32880181 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk, Cheese, Soy-based drink
Number of subjects: 11
Study 32880181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy products
Number of subjects: 11
Study 32880181 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy or Cheese intake
Number of subjects: 11
Study 32880181 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based drink intake
Number of subjects: 11
Study 34752019 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (10 μg, 2 doses, administered 21 days apart)
Number of subjects: 2268
Study 34752019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2268
Study 32747975 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS‐303 18 mg
Number of subjects: 16
Study 32747975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 34292606 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK3511294 (2, 10, 30, 100 or 300 mg)
Number of subjects: 48
Study 34292606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33023764 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma levels of total mono‐unsaturated fatty acids (MUFAs)
Number of subjects: 200
Study 33023764 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma levels of omega‐3 fatty acids
Number of subjects: 200
Study 33023764 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma levels of ruminant trans fatty acids
Number of subjects: 200
Study 33023764 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma levels of Arachidonic acid (omega‐6 fatty acid)
Number of subjects: 200
Study 33023764 — intervention group
Group type: COMPARATOR
Intervention: Total saturated fatty acids
Number of subjects: 200
Study 33023764 — intervention group
Group type: COMPARATOR
Intervention: Total industrial trans fats
Number of subjects: 200
Study 36910415 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-based training
Number of subjects: 198
Study 36910415 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 198
Study 35980115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 4541
Study 35980115 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 4541
Study 35980115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4541
Study 34422088 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model based on automatic image segmentation of DCE-MRI
Number of subjects: 81
Study 35460165 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of trazpiroben 25 mg after intravenous rifampin 600 mg (treatment B)
Number of subjects: 12
Study 35460165 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of trazpiroben 25 mg (treatment A)
Number of subjects: 12
Study 34587976 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32060166 — intervention group
Group type: EXPERIMENTAL
Intervention: BA and PST-informed rehabilitation intervention (BA/PS)
Number of subjects: 300
Study 32060166 — intervention group
Group type: COMPARATOR
Intervention: Time-matched attention control condition
Number of subjects: 300
Study 35726033 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day of oral vitamin D3
Number of subjects: 102
Study 35726033 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/day of oral vitamin D3
Number of subjects: 102
Study 33423600 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐min football
Number of subjects: 36
Study 33423600 — intervention group
Group type: COMPARATOR
Intervention: 60‐min seated rest (control)
Number of subjects: 36
Study 33423600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fit participants
Number of subjects: 36
Study 33423600 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fit participants
Number of subjects: 36
Study 33423600 — intervention group
Group type: EXPERIMENTAL
Intervention: Football
Number of subjects: 36
Study 32396412 — intervention group
Group type: EXPERIMENTAL
Intervention: six-CpG signature
Number of subjects: 378
Study 32396412 — intervention group
Group type: EXPERIMENTAL
Intervention: prognostic nomogram incorporating six-CpG signature, TNM stage, and age
Number of subjects: 378
Study 36399721 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 7013
Study 36399721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7013
Study 35590259 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted infant toilet training initiated at 0-2 months
Number of subjects: 268
Study 35590259 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted infant toilet training initiated during the first year of life
Number of subjects: 268
Study 33302976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised surfactant (Bovactant, Alveofact®) administered at varying doses (10 vials at 0, 8, and 24 hours or 30 vials at 24 hours)
Number of subjects: 20
Study 33302976 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised surfactant (Bovactant, Alveofact®)
Number of subjects: 20
Study 33302976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no placebo intervention)
Number of subjects: 20
Study 33683076 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) and laser hair removal
Number of subjects: 150
Study 33683076 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and laser hair removal
Number of subjects: 150
Study 33683076 — intervention group
Group type: COMPARATOR
Intervention: Laser hair removal alone
Number of subjects: 150
Study 32170438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty (V)
Number of subjects: 93
Study 32170438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 93
Study 33310565 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cochlear implants (CIs) on
Number of subjects: 18
Study 33310565 — intervention group
Group type: COMPARATOR
Intervention: Bilateral cochlear implants (CIs) off
Number of subjects: 18
Study 33310565 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving directional street sounds
Number of subjects: 18
Study 33310565 — intervention group
Group type: COMPARATOR
Intervention: Static white noise
Number of subjects: 18
Study 32432695 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-supported mobile intervention platform (IntelliCare) delivered over 8 weeks
Number of subjects: 146
Study 32432695 — intervention group
Group type: COMPARATOR
Intervention: Wait list control (treatment as usual for 8 weeks)
Number of subjects: 146
Study 33297742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia for 60 seconds
Number of subjects: 34
Study 33297742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia for 90 seconds
Number of subjects: 34
Study 33297742 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia for 30 seconds
Number of subjects: 34